Mitchell E. Taub

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 150 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY

Mitchell E. Taub, Lalitha Podila, Diane Ely et al. · Drug Metabolism and Disposition · 2005 · 125 citations

Medicine, Cell Biology, Pharmacology +15

Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I–IV

Mitchell E. Taub, Lisbeth Langholz Kristensen · European Journal of Pharmaceutical Sciences · 2002 · 77 citations

Pharmacy, Chemistry, Pharmaceutics +17

Differential Selectivity of Efflux Transporter Inhibitors in Caco-2 and MDCK–MDR1 Monolayers: A Strategy to Assess the Interaction of a New Chemical Entity with P-gp, BCRP, and MRP2

Kirsten Mease, Rucha Sane, Lalitha Podila et al. · Journal of Pharmaceutical Sciences · 2012 · 75 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Cocultured Human Hepatocyte System, HepatoPac

Diane Ramsden, Donald Tweedie, Tom S. Chan et al. · Drug Metabolism and Disposition · 2013 · 70 citations

Pharmacy, Pharmacokinetics, Pharmacology +17